mice and forms colonies in vitro has been used to test the correlation between 2 methods of exposure of human tumour cells to chemotherapeutic agents. In vivo exposure to drugs was achieved by injection of tumour-bearing mice with each of 8 cytotoxic agents. For the in vitro exposure, cell suspensions were incubated for 1 h with the same series of drugs. The survival of tumour clonogenic cells was assayed in vitro after either treatment or dose-response curves were obtained. The 8 drugs were ranked according to their in vivo effect at doses equitoxic to mice, and according to their in vitro effect at concentrations designed to approximate to levels of drugs in human plasma. The ranks for in vivo and in vitro exposure correlated well.
IT IS COMMON clinical experience that tumours of similar histology and stage show wide differences in response to cytotoxic drugs. This may be reflected clinically as differences in tumour-volume regression or, less commonly, as a difference between curative and non-curative therapy. Whilst factors such as drug distribution and metabolism, metastatic site and tumour volume may in part explain this variability, evidence from the experimental therapy of human tumour xenografts (Houghton et al., 1977; Nowak et al., 1978) supports the view that clinical differences in response reflect differences in intrinsic cellular chemosensitivity.
Since current methods of clinical drug evaluation are protracted and relatively imprecise, a predictive test of chemosensitivity would be advantageous for selecting active drugs from a range of currently used agents, and for testing new compounds. Previous attempts at in vitro tests for chemosensitivity of tumours have not met with great success (Mitchell et al., 1972; Berry et al., 1975) but methods which measuire depression of colonyforming ability of the tumour cells appear more promising (Salmon et al., 1978) . It is essential that the results of in vitro sensitivity tests satisfactorily reflect the tumour-cell kill that can be achieved in vrio. The present study is an attempt to validate an in vitro chemosensitivity test using a xenografted human tumour for which in vrio responses to drugs can be measured accurately in mice.
MATERIALS AND METHODS
The tumour used in this study was a poorly differentiated carcinoma of human pancreas (HX32, Courtenay & Mills, 1978) transplanted and passaged in the leg muscle of CBA/lac mice immune-suppressed by the method of Steel et al. (1978) . In brief, mice were thvmectomized at 4 weeks of age, and injected 2 weeks later with 200 mg/kg arabinosyl cytosine (Ara-C) i.p. 2 days before 900rad whole-body 60Co irradiation. and centrifugation at 600 g. Cells were resuspended in 1 ml Ham's medium plus SBCS, aliquots were counted on a haemacytometer, and cells diluted and plated as above. In all assays heavily irradiated cells (given 10,000 rad) were added to give a total cell concentration of 104/ml, to act as "feeder cells".
All liquids that had come into contact with the human tumour material were autoclaved before disposal; all plastics and glassware were either incinerated or immersed in hypochlorite solution before re-use.
Assessment of the in vitro cytotoxic activity of the 8 agents was made at drug concentrations selected on the basis of available information on human pharmacology. Human plasma concentrations at different times after conventional therapeutic doses of drug were obtained from the literature and replotted on a linear scale. The integral over the first hour after administration of the drug, and the integral of the whole plasma clearance curve were measured graphically. For HMM the lh peak value was the integral between 1.5 and 2-5 h after oral administration of the drug, as the peak plasma level occurred at 2 h (Bryan et al., 1968) . For adriamycin the sum of unchanged adriamycin and adriamycinol levels was used because, among the many metabolites, only adriamycinol is known to be cytotoxic (Benjamin et al., 1977) . The drugs used vary in their stability in in vitro systems. Melphalan, chlorambucil and thio-TEPA are the least stable and may have undergone some hydrolysis during the lh incubation. The decision to use a lh incubation for all the drugs was arbitrary. We recognize that the valid assessment of some drugs may require a longer or shorter time, and this will be the subject of subsequent research.
RESULTS
The clonogenic cell assay was used to measure cell survival after the HX32 tumours were exposed by injecting host mice with each cytotoxic agent. Fig. 1 shows the sensitivity of cells in this tumour, measured 20 h after a single (Freireich et al., 1966; Mellett, 1974; Goldsmith et al., 1975) . Table I Column 3 gives the surviving fraction of tumour cells at that dose. This fraction was read for each drug at the intersection of the dose-response curve with the vertical dotted line drawn at 1-0 on the abscissa. Fig. 1 shows the standard error of these values, as calculated from the regression analysis used to draw the curves, and the t test was used for differences between pairs of drugs. The resulting probabilities are shown in Table  I amine) was kindly given to us by C. J. Rutty. This compound showed no plateau of response (Fig. 5) . These results therefore support the conclusion that activation of HMM is needed for maximum cytotoxic effect.
In this preliminary study we have assessed the in vitro sensitivity of cells from HX32 tumour at concentrations derived by 2 alternative methods from human plasma clearance curves:
Comparison of in vivo and in vitro assessments of chemosensitivity As shown in Table III (Sutherland et al., 1979 Salmon et al. (1978) , using an alternative approach for defining in vitro sensitivity of cells from tumour biopsies, compared in vitro results with the response of patients. Their distinction between "resistance" and "sensitivity" in vitro was somewhat arbitrary, being based on the integral of a cell-survival vs drug-concentration curve with upper limits of 0a1 Hg/ml for melphalan and bleomycin, and 02 jug/ml for the other drugs used. Available pharmacological data indicate that melphalan, for example, gives a peak plasma level in patients of -1 jug/ml (Tattersall et al., 1978) , which is higher than the maximum concentration used in vitro by Salmon and his colleagues (1978) . If the 8 drugs of the present study had been assessed in vitro at a concentration of 1 Htg/ml, chlorambucil would have been ranked as the most effective drug followed by (2) melphalan, (3) thio-TEPA, (4) cisPt(II), (5) adriamycin, (6) methotrexate and (7) vinblastine. This correlates poorly with the in vivo ranking (P>0 05 for a Spearman rank correlation of 0 67). Thus the use of arbitrary drug concentrations in vitro precludes any effective ranking of drugs.
For the 8 drugs in this study, we conclude that HMM and adriamycin cannot be used in vitro to mimic in vivo response. For the other 6 drugs, lh in vitro exposures can be used to predict the in vivo effect of a single injection, if in vitro concentrations approximating to drug levels in patients' plasma are used.
Theoretically, the measurement of drug cytotoxicity at human plasma concentrations in vitro and at doses equitoxic to mice in vivo might both be expected to correlate with cytotoxicity in patients at drug doses equitoxic to man. The use of both these methods must be validated by studies on biopsy material from many human cancers and correlation of laboratory results with patients' responses.
However, we have demonstrated, using one human tumour xenograft, that the 2 assays correlate well with one another, and we therefore feel encouraged in our attempts to use the in vitro test for alkylating agents and cis-Pt(JJ) to compare the response of tumour biopsy material with patient response to chemotherapy. A study of this type is in progress, using ovarian carcinoma cells.
